Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
In patients with haemophilia A, factor VIII (FVIII) therapy leads to the development of anti-FVIII alloantibodies that inhibit FVIII pro-coagulant activity, in up to 25% of the cases. At a time when efficient viral screening procedures are at place, development of inhibitors poses the greatest threat to haemophilia A patients. Various risk factors, both patient and product-related, are responsible for the development of inhibitory antibodies. The role of FVIII-specific CD4+ T lymphocytes in the initiation of the humoral immune response to exogenous FVIII has been well. In view of their capacity to stimulate naïve T cells, dendritic cells (DCs) play a central role in the initiation of the primary immune response. Thus, in the context of a primary alloimmunization against FVIII, i.e. when FVIII-specific B lymphocytes are not there to take up FVIII from the circulation and to serve as antigen presenting cells (APCs), DCs are the only cell type that internalize FVIII, leading to activation of FVIII-specific CD4+ T lymphocytes. von Willebrand factor (VWF) present in plasma-derived FVIII therapeutic concentrates, is known to act as a chaperone molecule for procoagulant FVIII. In addition to its role in reducing the 'antigenicity' of FVIII, the role of VWF in the reduction of the 'immunogenicity' of therapeutic FVIII in patients with haemophilia A has also been suggested. We have recently demonstrated that VWF protects FVIII from being endocytosed by human DCs and subsequently being presented to FVIII-specific T cells. We propose that VWF may reduce the immunogenicity of FVIII by preventing, upstream from the activation of immune effectors, the entry of FVIII in professional antigen presenting cells.
Kaveri
S V
SV
Centre de Recherche des Cordeliers, Université Pierre et Marie Curie-Paris 6, UMR S872, Paris, F-75006, France. srini.kaveri@umrs681.jussieu.fr
Dasgupta
S
S
Andre
S
S
Navarrete
A-M
AM
Repessé
Y
Y
Wootla
B
B
Lacroix-Desmazes
S
S
D017951:Antigen Presentation; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D003029:Coagulants / Q000276:immunology* / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology*; D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007108:Immune Tolerance; D007518:Isoantibodies / Q000276:immunology*; D008213:Lymphocyte Activation; D014841:von Willebrand Factor / Q000502:physiology*
D003029:Coagulants; D007518:Isoantibodies; D014841:von Willebrand Factor; D005169:Factor VIII